Discussion Forum (0)
At the end of this programme, participants will be able to:
- Evaluate the benefits and risks of various treatment options across the treatment continuum in BCa, RCC, and PCa.
- Discuss strategies to identify and manage adverse events related to immunotherapy.
- Evaluate the role of immunotherapy vs VEGF-targeted therapies for RCC.
- Evaluate the role of imaging or biomarkers vs biopsy in active surveillance for localized prostate cancer.
- Discuss strategies for managing oligometastatic disease.
- Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.
Code of conduct/disclaimer available in
General Terms & Conditions
{{ help_message }}
{{filter}}